Dr. Saran Saund, Chief Business Officer, Oncotelic Therapeutics is an immuno-oncology company dedicated to developing RNA cancer therapies for melanoma and pancreatic cancer using their nano molecular therapy platform.  Using AI they recently screened several of their own molecules and ethnobotanicals for COVID-19.  As a result Oncotelic has developed a compound based on an ancient ayurvedic artemisinin-based therapy using the active ingredient from the plant artemisia, also known as sweet wormwood. The tablet formulation of ARTIVeda would allow for efficient distribution to a global audience at a fraction of the cost of current therapies like Remdesivir. #Oncotelic #COVID19 #COVIDTherapies #ARTIVeda Oncotelic.com Download the transcript here